Results 251 to 260 of about 72,749 (293)
Some of the next articles are maybe not open access.

Drug-Eluting Stents

Annual Review of Medicine, 2004
Advances in catheter and stent design have made stent implantation the standard coronary angioplasty procedure. Unfortunately, in-stent restenosis continues to plague this procedure, with the optimum binary restenosis rates reaching ∼10% to 20%. In the past few years, it has become clear that in-stent restenosis is largely due to the migration and ...
Andrew R. Marks, T Cooper Woods
openaire   +6 more sources

Drug-eluting stents [PDF]

open access: possible, 2012
Imad Sheiban has been Associated Professor of Cardiology at the University of Turin, Italy since 2003. Since 1989, he has performed approximately 10,000 procedures of interventional cardiology. He is actively involved in different research programs participating to several international multicenter trials.
Imad Sheiban, Fabrizio D'Ascenzo
openaire   +2 more sources

Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.

Journal of the American Medical Association (JAMA), 2005
CONTEXT Traditionally, stent thrombosis has been regarded as a complication of percutaneous coronary interventions during the first 30 postprocedural days.
I. Iakovou   +15 more
semanticscholar   +1 more source

Drug-eluting stents: a reappraisal [PDF]

open access: possibleHeart, 2010
The introduction of drug-eluting stents (DES) in 2002 revolutionised the field of percutaneous coronary intervention (PCI), by significantly reducing rates of restenosis when compared to bare-metal stents (BMS).1 Following this there was a rapid and unprecedented uptake in their use, such that within a matter of years they were used in approximately 80–
Scot Garg, Patrick W. Serruys
openaire   +2 more sources

Drug‐Coated balloons vs drug‐eluting stents for the treatment of small coronary artery disease: A meta‐analysis of randomized trials

Catheterization and cardiovascular interventions, 2020
There is conflicting evidence about the effects of drug‐coated balloons (DCB) compared with drug‐eluting stents (DES) in patients with native small vessel coronary artery disease (CAD).
J. Sanz Sánchez   +7 more
semanticscholar   +1 more source

Optical coherence tomography study of healing characteristics of paclitaxel-eluting balloons vs. everolimus-eluting stents for in-stent restenosis: the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) randomised clinical trial.

EuroIntervention, 2014
AIMS Little is known about the respective healing responses and clinical efficacy and safety of drug-eluting balloons (DEB) and the second generation of drug-eluting stents (DES) when used to treat in-stent restenosis (ISR).
T. Adriaenssens   +11 more
semanticscholar   +1 more source

An Update on Drug-Eluting Stents

Current Treatment Options in Cardiovascular Medicine, 2012
Coronary artery disease remains one of the major causes of morbidity and mortality worldwide. Percutaneous coronary intervention has been shown to be an effective treatment for angina pectoris, although it does not provide any prognostic benefit in stable patients.
Scot Garg, Patrick W. Serruys
openaire   +4 more sources

Drug-eluting stents: a critique [PDF]

open access: possibleHeart, 2008
Despite advances in the design of balloons and stents, restenosis remains a major drawback of coronary angioplasty. Multiple randomised trials have demonstrated that drug-eluting stents (DES) can significantly reduce rates of restenosis by 60-75% across both lesion and patient subsets.
William Wijns, Narbeh Melikian
openaire   +2 more sources

Safety of drug-eluting stents

Nature Clinical Practice Cardiovascular Medicine, 2008
Drug-eluting stents (DESs) effectively reduce angiographic restenosis and the clinical need for repeat revascularization procedures as compared with bare-metal stents. Widely publicized concerns arose recently about the incidence of late and very late stent thrombosis with the use of first-generation DESs.
Peter Jüni, Stephan Windecker
openaire   +3 more sources

Drug‐Eluting Stents

In Vitro Drug Release Testing of Special Dosage Forms, 2019
Anne Seidlitz
semanticscholar   +3 more sources

Home - About - Disclaimer - Privacy